P1076 (DAIDS ID 10669): Impact of Oral Alendronate Therapy on Bone Mineral Density in HIV-Infected Children and Adolescents with Low Bone Mineral Density at Baseline

Study Status Study Restriction

Closed to Follow Up

US & Non-US

What is P1076?

P1076 is randomized, placebo-controlled, double blind pilot study of oral alendronate therapy in HIV-infected participants ≥ 11 to < 25 years of age not on antiretroviral treatment or on stable antiretroviral treatment and with low bone mineral density.  The study is designed to estimate and compare changes from pre-treatment levels in BMD of the lumbar spine and to assess the safety of alendronate.

Study Documents:

Sites where the study is implemented:

CRS ID Site Name City Country

5073

SOM Federal University Minas Gerais Brazil

Minas Gerais

Brazil

5074

Univ of Sao Paulo Brazil

Sao Paulo

Brazil

4001

Chicago Children's CRS

Chicago

United States of America

4201

University of Miami Pediatric/Perinatal HIV/AIDS

Miami

United States of America

5031

San Juan City Hospital

San Juan

United States of America

5092

Johns Hopkins University, Baltimore

Baltimore

United States of America

5112

UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CR

Los Angeles

United States of America

6501

St. Jude/UTHSC CRS

Memphis

United States of America

Study contacts:

Clinical Trials Specialist: Kathleen George

 

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.